Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
暂无分享,去创建一个
[1] E. Zuhowski,et al. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Jodrell,et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. George. Statistical considerations and modeling of clinical utility of tumor markers. , 1994, Hematology/oncology clinics of North America.
[4] D. Jodrell,et al. Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial , 1993 .
[5] M Mazumdar,et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Miller,et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.
[7] J. Oesterling,et al. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.
[8] S. Dawsey,et al. Validation of intermediate end points in cancer research. , 1990, Journal of the National Cancer Institute.
[9] N. Geller,et al. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[11] D. Seigel,et al. Surrogate endpoints in clinical trials: ophthalmologic disorders. , 1989, Statistics in medicine.
[12] J. Herson. The use of surrogate endpoints in clinical trials (an introduction to a series of four papers) , 1989 .
[13] J R Anderson,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Logothetis,et al. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M H Gail,et al. Evaluating serial cancer marker studies in patients at risk of recurrent disease. , 1981, Biometrics.
[16] J. Minna,et al. Effective treatment of hormonally‐unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide methods of documenting tumor response and progression , 1980, Cancer.
[17] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[18] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[19] J. Swets,et al. A decision-making theory of visual detection. , 1954, Psychological review.
[20] D. Jodrell,et al. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .